Vaccine, Nov 20, 2012, Vol.30, p.F139-F148
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.vaccine.2012.05.039 Byline: Lauri E. Markowitz (a), Vivien Tsu (b), Shelley L. Deeks (c), Heather Cubie (d), Susan A. Wang (e), Andrea S. Vicari (f), Julia M.L. Brotherton (g) Keywords: HPV; vaccine introduction; vaccine acceptability Abstract: a* National HPV vaccination programs had been introduced in over 39 countries by the beginning of 2012. a* Most countries that have introduced vaccine are high income countries. a* Different health care systems/infrastructure have resulted in varied implementation. a* Substantial post-licensure safety data accumulated to date are reassuring. a* HPV introduction has generated considerable debate in some countries. Author Affiliation: (a) Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, Georgia, 30333, US (b) PATH, P.O. Box 900922, Seattle, Washington, 98109, US (c) Public Health Ontario, 480 University Ave, Suite 300, Toronto, Ontario M5G1V2, Canada (d) National HPV Reference Laboratory, Royal Infirmary of Edinburgh, 51 Little France Cres, Edinburgh EH16 4SA, Scotland (e) Expanded Programme on Immunization, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland (f) Comprehensive Family Immunization Project, Pan American Health Organization, Apartado 3745, San Jose, Costa Rica (g) Victorian Cytology Service Registries, PO Box 310, East Melbourne, Victoria 8002, Australia Article History: Received 10 February 2012; Revised 7 May 2012; Accepted 8 May 2012
Papillomavirus Infections ; Vaccines ; Public Health ; Vaccination
Cengage Learning, Inc.